A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin

Abstract Background Investigate the impact of interval cytoreductive surgery (ICS) on progression in an orthotopic mouse model of ovarian cancer and the impact of chemotherapy delivered at various timelines following surgery. Methods Luciferase-expressing ID8 murine ovarian cancer cells were implant...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mitchell Clark, Alexandra Kollara, Theodore J. Brown, Taymaa May
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Ovarian cancer Neoadjuvant chemotherapy Cisplatin Cytoreductive surgery Mouse ID8 cells Gynecology and obstetrics RG1-991
Acceso en línea:	https://doaj.org/article/781c9d853603453e9768bdbb3a959149
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:781c9d853603453e9768bdbb3a959149
record_format	dspace
spelling	oai:doaj.org-article:781c9d853603453e9768bdbb3a9591492021-11-21T12:32:07ZA mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin10.1186/s13048-021-00895-w1757-2215https://doaj.org/article/781c9d853603453e9768bdbb3a9591492021-11-01T00:00:00Zhttps://doi.org/10.1186/s13048-021-00895-whttps://doaj.org/toc/1757-2215Abstract Background Investigate the impact of interval cytoreductive surgery (ICS) on progression in an orthotopic mouse model of ovarian cancer and the impact of chemotherapy delivered at various timelines following surgery. Methods Luciferase-expressing ID8 murine ovarian cancer cells were implanted intra-bursally and IP to C57BL/7 mice. Once disease was established by bioluminescence, 2 cycles of neoadjuvant cisplatin were administered, and animals received either ICS (removal of the injected bursa/primary tumor) or anesthesia alone. Postsurgical chemotherapy was administered on the same day as the intervention (ICS/anesthesia), or on day 7 or day 28 following the intervention. Progression was quantified serially with in vivo bioluminescence imaging. Volume of ascitic fluid volume collected at necropsy was measured. Results Animals were matched for tumor burden at stratification. There was no accelerated growth of residual tumor after interval cytoreduction compared to controls. Animals who received chemotherapy on postoperative day (POD) 7 had better disease control compared to standard-of-care POD 28. Animals who underwent surgery had less ascites at necropsy compared to those who had anesthesia alone. Conclusions In this animal model, surgical wounding with suboptimal cytoreduction after neoadjuvant chemotherapy did not cause accelerated expansion of residual disease. Surgical wounding appears to impair cisplatin activity when given at time of surgery.Mitchell ClarkAlexandra KollaraTheodore J. BrownTaymaa MayBMCarticleOvarian cancerNeoadjuvant chemotherapyCisplatinCytoreductive surgeryMouseID8 cellsGynecology and obstetricsRG1-991ENJournal of Ovarian Research, Vol 14, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ovarian cancer Neoadjuvant chemotherapy Cisplatin Cytoreductive surgery Mouse ID8 cells Gynecology and obstetrics RG1-991
spellingShingle	Ovarian cancer Neoadjuvant chemotherapy Cisplatin Cytoreductive surgery Mouse ID8 cells Gynecology and obstetrics RG1-991 Mitchell Clark Alexandra Kollara Theodore J. Brown Taymaa May A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
description	Abstract Background Investigate the impact of interval cytoreductive surgery (ICS) on progression in an orthotopic mouse model of ovarian cancer and the impact of chemotherapy delivered at various timelines following surgery. Methods Luciferase-expressing ID8 murine ovarian cancer cells were implanted intra-bursally and IP to C57BL/7 mice. Once disease was established by bioluminescence, 2 cycles of neoadjuvant cisplatin were administered, and animals received either ICS (removal of the injected bursa/primary tumor) or anesthesia alone. Postsurgical chemotherapy was administered on the same day as the intervention (ICS/anesthesia), or on day 7 or day 28 following the intervention. Progression was quantified serially with in vivo bioluminescence imaging. Volume of ascitic fluid volume collected at necropsy was measured. Results Animals were matched for tumor burden at stratification. There was no accelerated growth of residual tumor after interval cytoreduction compared to controls. Animals who received chemotherapy on postoperative day (POD) 7 had better disease control compared to standard-of-care POD 28. Animals who underwent surgery had less ascites at necropsy compared to those who had anesthesia alone. Conclusions In this animal model, surgical wounding with suboptimal cytoreduction after neoadjuvant chemotherapy did not cause accelerated expansion of residual disease. Surgical wounding appears to impair cisplatin activity when given at time of surgery.
format	article
author	Mitchell Clark Alexandra Kollara Theodore J. Brown Taymaa May
author_facet	Mitchell Clark Alexandra Kollara Theodore J. Brown Taymaa May
author_sort	Mitchell Clark
title	A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
title_short	A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
title_full	A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
title_fullStr	A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
title_full_unstemmed	A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
title_sort	mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
publisher	BMC
publishDate	2021
url	https://doaj.org/article/781c9d853603453e9768bdbb3a959149
work_keys_str_mv	AT mitchellclark amousemodelofneoadjuvantchemotherapyfollowedbyintervalcytoreductivesurgeryindicatesimpairedefficacyofperioperativecisplatin AT alexandrakollara amousemodelofneoadjuvantchemotherapyfollowedbyintervalcytoreductivesurgeryindicatesimpairedefficacyofperioperativecisplatin AT theodorejbrown amousemodelofneoadjuvantchemotherapyfollowedbyintervalcytoreductivesurgeryindicatesimpairedefficacyofperioperativecisplatin AT taymaamay amousemodelofneoadjuvantchemotherapyfollowedbyintervalcytoreductivesurgeryindicatesimpairedefficacyofperioperativecisplatin AT mitchellclark mousemodelofneoadjuvantchemotherapyfollowedbyintervalcytoreductivesurgeryindicatesimpairedefficacyofperioperativecisplatin AT alexandrakollara mousemodelofneoadjuvantchemotherapyfollowedbyintervalcytoreductivesurgeryindicatesimpairedefficacyofperioperativecisplatin AT theodorejbrown mousemodelofneoadjuvantchemotherapyfollowedbyintervalcytoreductivesurgeryindicatesimpairedefficacyofperioperativecisplatin AT taymaamay mousemodelofneoadjuvantchemotherapyfollowedbyintervalcytoreductivesurgeryindicatesimpairedefficacyofperioperativecisplatin
_version_	1718418952892186624

A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin

Ejemplares similares